利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

64 条记录 (耗时 0.046 秒)

    Continuous casting method for steel and method for manufacturing steel sheet
    31.
    发明授权
    Continuous casting method for steel and method for manufacturing steel sheet 有权
    钢的连续铸造方法和钢板的制造方法

    公开(公告)号：US08596334B2

    公开(公告)日：2013-12-03

    申请号：US13583487

    申请日：2011-03-09

    申请人： Yuji Miki ,  Takeshi Murai ,  Hiroyuki Ohno

    发明人： Yuji Miki ,  Takeshi Murai ,  Hiroyuki Ohno

    IPC分类号： B22D11/115

    CPC分类号： B22D11/103 ,  B21B1/22 ,  B22D11/115 ,  B22D11/122 ,  C22C38/06 ,  C22C38/12 ,  C22C38/14

    摘要： In a method for continuously casting an extremely low carbon steel using a continuous casting machine, by adjusting the chemical components of extremely low carbon steel within a specified range by taking into account an interface tension gradient in a concentration boundary layer on a front surface of a solidified shell, and also by optimizing intensities of the DC magnetic fields applied to the upper magnetic poles and the lower magnetic poles respectively corresponding to a slab width of a slab to be casted and a casting speed, it is possible to acquire the slab having high quality not only with the small number of defects caused by the entrainment of bubbles, non-metallic inclusion and a mold flux into the molten steel.

    摘要翻译： 在使用连续铸造机连续铸造极低碳钢的方法中，通过考虑到在特定范围内的浓度边界层的界面张力梯度，将极低碳钢的化学成分调整到规定范围内 固化壳，并且通过优化分别对应于要铸造的板坯的板坯宽度和铸造速度的上磁极和下磁极施加的DC磁场的强度，可以获得具有高的 质量不仅具有由于气泡夹带，非金属夹杂物和模具通量进入钢水引起的少量缺陷。

    Pentanoic acid derivatives
    32.
    发明授权
    Pentanoic acid derivatives 失效
    戊酸衍生物

    公开(公告)号：US07569609B2

    公开(公告)日：2009-08-04

    申请号：US11192004

    申请日：2005-07-29

    申请人： Shuichi Ohuchida ,  Kazuo Kishimoto ,  Narito Tateishi ,  Hiroyuki Ohno

    发明人： Shuichi Ohuchida ,  Kazuo Kishimoto ,  Narito Tateishi ,  Hiroyuki Ohno

    IPC分类号： A61K31/19 ,  A61K31/192 ,  A61K31/20

    CPC分类号： C07D213/75 ,  A61K31/19 ,  C07C53/21 ,  C07C69/612 ,  C07C69/63 ,  C07C69/708 ,  C07C233/05 ,  C07C233/11 ,  C07C233/25 ,  C07C233/47 ,  C07C233/54 ,  C07C323/52 ,  C07D295/185

    摘要： Formula (I) compounds: wherein R1 is alkyl substituted by fluorine(s); R2 is hydroxy, alkoxy, alkoxy substituted by phenyl, NR3R4, in which R3, R4 is (i) hydrogen, (ii) alkyl, (iii) phenyl, (iv) phenyl substituted by alkoxy or carboxyl, (v) heterocyclic ring containing nitrogen atom, (vi) alkyl substituted by phenyl, phenyl subsituted by alkoxy or carboxyl, heterocyclic ring containing nitrogen atom, (vii) the nitrogen bonded to R3 and R4, taken together is a saturated heterocyclic ring or amino acid residue; and non-toxic salts and acid addition salts thereof. Also, Formula (X) compounds: wherein n is 0 or 1, R11 is hydrogen and chlorine, R5 is R7—CH2— or R8, or R5 and R11, taken together is alkylidene; R6 is hydroxy, alkoxy, alkoxy substituted by phenyl, NR9R10, in which R9, R10 is (i) hydrogen, (ii) alkyl, (iii) phenyl, (iv) phenyl substituted by alkoxy or carboxyl, (v) heterocyclic ring containing nitrogen atom, (vi) alkyl substituted by phenyl, phenyl-substituted by alkoxy or carboxyl, heterocyclic ring containing nitrogen atom, (vii) the nitrogen bonded to R9 and R10, taken together is a saturated heterocyclic ring or amino acid residue, R7 is (i) F—(CH2)m- or F3C—CH2—, (ii) alkyl substituted by chlorine, (iii) alkyl substituted by alkoxy, cycloalkyl, phenyl, phenoxy; R8 is alkyl, alkenyl, alkoxy, alkylthio, cycloalkyl, phenyl, phenoxy. Non-toxic and acid addition salts thereof are useful to prevent and/or treat neurodegenerative disease (e.g., Alzheimer's) and neuronal dysfunction by stroke or traumatic injury (e.g., Multiple sclerosis).

    摘要翻译： 式（I）化合物：其中R1是被氟取代的烷基; R2是羟基，烷氧基，被苯基取代的烷氧基，NR3R4，其中R3，R4是（i）氢，（ii）烷基，（iii）苯基，（iv）被烷氧基或羧基取代的苯基，（v） 氮原子，（vi）被苯基取代的烷基，被烷氧基或羧基取代的苯基，含有氮原子的杂环，（vii）与R3和R4键合的氮原子一起是饱和杂环或氨基酸残基; 及其无毒盐及其酸加成盐。 另外，式（X）化合物：其中n为0或1，R11为氢和氯，R5为R7-CH2-或R8，或R5和R11为亚烷基; R6是羟基，烷氧基，被苯基取代的烷氧基，NR9R10，其中R9，R10是（i）氢，（ii）烷基，（iii）苯基，（iv）被烷氧基或羧基取代的苯基，（v） 氮原子，（vi）被苯基取代的烷基，被烷氧基或羧基取代的苯基，含氮原子的杂环，（vii）与R 9和R 10结合的氮一起是饱和的杂环或氨基酸残基，R7是 （ⅰ）F-（CH2）m-或F3C-CH2-，（ⅱ）被氯取代的烷基，（ⅲ）被烷氧基，环烷基，苯基，苯氧基取代的烷基; R8是烷基，烯基，烷氧基，烷硫基，环烷基，苯基，苯氧基。 其无毒和酸加成盐可用于预防和/或治疗神经变性疾病（例如阿尔茨海默氏症）和神经元功能障碍（卒中或创伤性损伤（例如多发性硬化））。

    Polypeptide of protein p140 and DNAs encoding it
    36.
    发明授权
    Polypeptide of protein p140 and DNAs encoding it 失效
    蛋白质p140的多肽和编码它的DNA

    公开(公告)号：US06432913B1

    公开(公告)日：2002-08-13

    申请号：US09558340

    申请日：2000-04-26

    申请人： Hisao Tajima ,  Koichiro Kitagawa ,  Hiroyuki Ohno

    发明人： Hisao Tajima ,  Koichiro Kitagawa ,  Hiroyuki Ohno

    IPC分类号： A01N6100

    CPC分类号： C07K14/47 ,  A61K38/00

    摘要： The present invention is related to a novel protein p140 polypeptide which is a key protein involved in the signal transmission system of insulin; method for preparation of it; DNA encoding the said polypeptide; vector derived the said DNA; host cells transformed the said vector; antibody of the said polypeptide; pharmaceutical composition containing the said peptide or antibody; method for the prevention and/or treatment of diabetes, which is characterized by tyrosine phosphorylation of the said protein p140; agent for the prevention and/or treatment for the currently said the prevention and/or treatment method; agent for the prevention and/or treatment of diabetes, which is characterized by containing a compound which can tyrosine phosphorylation of protein p140, as active ingredient and the screening methods of the said prevention and/or treatment agent. Tyrosine phosphorylation of protein p140 is an essential step in the induction of hypoglycemia by glucose uptake. Method and agent of prevention and/or treatment based on tyrosine phosphorylation of protein p140 in the present invention is not only improve the diabetes-derived hyperglycemic conditions but are also useful for the treatment and/or prevention of diabetes, especially non-insulin dependent diabetes mellitus (NIDDM).

    摘要翻译： 本发明涉及胰岛素信号传递系统中涉及的关键蛋白质的新型蛋白质p140多肽， 制备方法 编码所述多肽的DNA; 载体衍生所述DNA; 宿主细胞转化所述载体; 所述多肽的抗体; 含有所述肽或抗体的药物组合物; 用于预防和/或治疗糖尿病的方法，其特征在于所述蛋白质p140的酪氨酸磷酸化; 用于预防和/或治疗目前所述的预防和/或治疗方法的药剂; 用于预防和/或治疗糖尿病的药物，其特征在于含有可以作为活性成分的蛋白质p140的酪氨酸磷酸化的化合物和所述预防和/或治疗剂的筛选方法。蛋白质p140的酪氨酸磷酸化是 通过葡萄糖摄取诱导低血糖的关键步骤。 本发明中基于蛋白质p140的酪氨酸磷酸化的预防和/或治疗方法和药剂不仅可以改善糖尿病来源的高血糖状况，而且可用于治疗和/或预防糖尿病，特别是非胰​​岛素依赖型糖尿病 （NIDDM）。

    Tetrazole compounds and pharmaceutical agents containing such derivative as an active ingredient
    37.
    发明授权
    Tetrazole compounds and pharmaceutical agents containing such derivative as an active ingredient 失效
    含有这种衍生物作为活性成分的四唑化合物和药剂

    公开(公告)号：US06376484B1

    公开(公告)日：2002-04-23

    申请号：US09572569

    申请日：2000-05-16

    申请人： Kazuyuki Ohmoto ,  Makoto Tanaka ,  Tohru Miyazaki ,  Hiroyuki Ohno

    发明人： Kazuyuki Ohmoto ,  Makoto Tanaka ,  Tohru Miyazaki ,  Hiroyuki Ohno

    IPC分类号： A61K3155

    CPC分类号： C07D257/04 ,  A61K38/00 ,  C07D401/06 ,  C07D403/06 ,  C07D403/12 ,  C07D403/14 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07K5/0205 ,  C07K5/06052 ,  C07K5/06139

    摘要： A tetrazole derivatives of formula (I) wherein R1 is H, alkyl, alkoxy, carbocyclic ring, hetero ring, alkyl or alkoxy substituted by carbocyclic ring or hetero ring, etc.; AA1 is bond or  AA2 is bond or  AA1 and AA2, together, may have the formula (a);  Y is the formula (b) (in which Tet ring is tetrazole; Z is alkylene, alkenylene, O, S, SO, SO2, NR26, methylene in alkylene replaced by O, S, —SO—, —SO2— or —NR26—; E is H, alkyl, COOR27 or  in which Cyc is carbocyclic ring or hetero ring); a non-toxic salt thereof, an acid addition salt thereof or a hydrate thereof which has a pharmaceutical agents as an active ingredient. The compound of the formula (I) has an inhibitory effect on interleukin-1&bgr; converting enzyme, therefore, they are useful for prevention and/or treatment of various kinds of inflammatory disease.

    摘要翻译： 式（I）的四唑衍生物，其中R 1为H，烷基，烷氧基，碳环，杂环，被碳环或杂环取代的烷基或烷氧基等; AA1是键或AA2是键或AA1和AA2，一起可以具有式（a）; Y是式（b）（其中Tet环是四唑; Z是亚烷基，亚烯基，O，S，SO，SO 2，NR 26，亚烷基被O，S，-SO-，-SO 2 - 或-NR 26 - ; E是H，烷基，COOR 27或其中Cyc是碳环或杂环）;其无毒盐，其酸加成盐或其水合物，其具有药剂作为活性成分。 式（I）的化合物对白细胞介素-1β转换酶具有抑制作用，因此可用于预防和/或治疗各种炎性疾病。

    Polypeptide of protein P140 and DNAs encoding it
    38.
    发明授权
    Polypeptide of protein P140 and DNAs encoding it 失效
    蛋白P140的多肽和编码它的DNA

    公开(公告)号：US06303320B1

    公开(公告)日：2001-10-16

    申请号：US09192435

    申请日：1998-01-08

    申请人： Hisao Tajima ,  Koichiro Kitagawa ,  Hiroyuki Ohno

    发明人： Hisao Tajima ,  Koichiro Kitagawa ,  Hiroyuki Ohno

    IPC分类号： G01N3353

    CPC分类号： C07K14/47 ,  A61K38/00

    摘要： The present invention is related to a novel protein p140 polypeptide which is a key protein involved in the signal transmission system of insulin; method for preparation of it; DNA encoding the polypeptide; vector derived with the DNA; host cells transformed with the vector; antibody of the polypeptide; pharmaceutical composition containing the peptide or antibody; method for the prevention and/or treatment of diabetes, which is characterized by tyrosine phosphorylation of the protein p140; agent for the prevention and/or treatment of diabetes, which is characterized by containing a compound which can tyrosine phosphorylate protein p140, as active ingredient and the screening methods of the prevention and/or treatment agent. Tyrosine phosphorylation of protein p140 is an essential step in the induction of hypoglycemia by glucose uptake. Method and agent of prevention and/or treatment based on tyrosine phosphorylation of protein p140 in the present invention not only improve the diabetes-derived hyperglycemic conditions but are also useful for the treatment and/or prevention of diabetes, especially non-insulin dependent diabetes mellitus (NIDDM).

    摘要翻译： 本发明涉及胰岛素信号传递系统中涉及的关键蛋白质的新型蛋白质p140多肽， 制备方法 编码多肽的DNA; 用DNA衍生的载体; 宿主细胞用载体转化; 多肽的抗体; 含有肽或抗体的药物组合物; 用于预防和/或治疗糖尿病的方法，其特征在于蛋白质p140的酪氨酸磷酸化; 用于预防和/或治疗糖尿病的药物，其特征在于含有可以酪氨酸磷酸化蛋白质p140的化合物作为活性成分和预防和/或治疗剂的筛选方法。 蛋白质p140的酪氨酸磷酸化是通过葡萄糖摄取诱导低血糖的关键步骤。 本发明中基于蛋白质p140的酪氨酸磷酸化的预防和/或治疗方法和药剂不仅改善糖尿病衍生的高血糖病症，而且可用于治疗和/或预防糖尿病，特别是非胰​​岛素依赖性糖尿病 （NIDDM）。

    Pentanoic acid derivatives
    39.
    发明授权
    Pentanoic acid derivatives 失效
    戊酸衍生物

    公开(公告)号：US06201021B1

    公开(公告)日：2001-03-13

    申请号：US08681482

    申请日：1996-07-23

    申请人： Shuichi Ohuchida ,  Kazuo Kishimoto ,  Narito Tateishi ,  Hiroyuki Ohno

    发明人： Shuichi Ohuchida ,  Kazuo Kishimoto ,  Narito Tateishi ,  Hiroyuki Ohno

    IPC分类号： A61K3119

    CPC分类号： C07D213/75 ,  A61K31/19 ,  C07C53/21 ,  C07C69/612 ,  C07C69/63 ,  C07C69/708 ,  C07C233/05 ,  C07C233/11 ,  C07C233/25 ,  C07C233/47 ,  C07C233/54 ,  C07C323/52 ,  C07D295/185

    摘要： Formula (I) compounds: wherein R1 is alkyl substituted by fluorine(s); R2 is hydroxy, alkoxy, alkoxy substituted by phenyl, NR3R4, in which R3, R4 is (i) hydrogen, (ii) alkyl, (iii) phenyl, (iv) phenyl substituted by alkoxy or carboxyl, (v) heterocyclic ring containing nitrogen atom, (vi) alkyl substituted by phenyl, phenyl subsituted by alkoxy or carboxyl, heterocyclic ring containing nitrogen atom, (vii) the nitrogen bonded to R3 and R4, taken together is a saturated heterocyclic ring or amino acid residue; and non-toxic salts and acid addition salts thereof. Also, Formula (X) compounds: wherein n is 0 or 1, R11 is hydrogen and chlorine, R5 is R7—CH2— or R8, or R5 and R11, taken together is alkylidene; R6 is hydroxy, alkoxy, alkoxy substituted by phenyl, NR9R10, in which R9, R10 is (i) hydrogen, (ii) alkyl, (iii) phenyl, (iv) phenyl substituted by alkoxy or carboxyl, (v) heterocyclic ring containing nitrogen atom, (vi) alkyl substituted by phenyl, phenyl-substituted by alkoxy or carboxyl, heterocyclic ring containing nitrogen atom, (vii) the nitrogen bonded to R9 and R10, taken together is a saturated heterocyclic ring or amino acid residue, R7 is (i) F—(CH2)m— or F3C—CH2—, (ii) alkyl subsstituted by chlorine, (iii) alkyl substituted by alkoxy, cycloalkyl, phenyl, phenoxy; R8 is alkyl, alkenyl, alkoxy, alkylthio, cycloalkyl, phenyl, phenoxy. Non-toxic and acid addition salts thereof are useful to prevent and/or treat neurodegenerative disease (e.g., Alzheimer's) and neuronal dysfunction by stroke or traumatic injury (e.g., Multiple sclerosis).

    摘要翻译： 式（I）化合物：其中R1是被氟取代的烷基; R2是羟基，烷氧基，被苯基取代的烷氧基，NR3R4，其中R3，R4是（i）氢，（ii）烷基，（iii）苯基，（iv）被烷氧基或羧基取代的苯基，（v） 氮原子，（vi）被苯基取代的烷基，被烷氧基或羧基取代的苯基，含有氮原子的杂环，（vii）与R3和R4键合的氮原子一起是饱和杂环或氨基酸残基; 及其无毒盐及其酸加成盐。 另外，式（X）化合物：其中n为0或1，R11为氢和氯，R5为R7-CH2-或R8，或R5和R11为亚烷基; R6是羟基，烷氧基，被苯基取代的烷氧基，NR9R10，其中R9，R10是（i）氢，（ii）烷基，（iii）苯基，（iv）被烷氧基或羧基取代的苯基，（v） 氮原子，（vi）被苯基取代的烷基，被烷氧基或羧基取代的苯基，含氮原子的杂环，（vii）与R 9和R 10结合的氮一起是饱和的杂环或氨基酸残基，R7是 （ⅰ）F-（CH2）m-或F3C-CH2-，（ⅱ）由氯取代的烷基，（ⅲ）被烷氧基，环烷基，苯基，苯氧基取代的烷基; R8是烷基，烯基，烷氧基，烷硫基，环烷基，苯基，苯氧基。 其无毒和酸加成盐可用于预防和/或治疗神经变性疾病（例如阿尔茨海默氏症）和神经元功能障碍（卒中或创伤性损伤（例如多发性硬化））。